Evidence for Pharmacogenomic Effects on Risperidone Outcomes in Pediatrics.

ABSTRACT:

Objective

To determine the association between genetic variants reported to affect risperidone and adverse events (AEs) in children and adolescents.

Methods

Individuals aged 18 years or younger with ≥4 weeks of risperidone exposure in a deidentified DNA biobank were included. The primary outcome was AE frequency as a function of genotype. Individuals were classified according to metabolizer status for CYP2D6, CYP3A4, and CYP3A5; wild type, heterozygote, or homozygote for specific single nucleotide variants for DRD2, DRD3, HTR2A, and HTR2C; and wild type versus nonwild type for multiple uncommon variants in ABCG2, ABCB1, and HTR2C. Tests of association of each classification to AEs were performed using a Fisher exact test and logistic regression, and statistically significant

SUBMITTER: Rossow KM 

PROVIDER: S-EPMC7995603 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature